Mirna Therapeutics Inc. (NASDAQ:MIRN) was downgraded by research analysts at Cantor Fitzgerald from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, The Fly reports.

MIRN has been the topic of several other reports. HC Wainwright initiated coverage on Mirna Therapeutics in a research report on Monday, September 12th. They set a “buy” rating and a $6.00 price target on the stock. Zacks Investment Research upgraded Mirna Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research report on Wednesday, September 7th. Citigroup Inc. lowered Mirna Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the company from $7.00 to $4.50 in a research report on Tuesday, August 16th. Oppenheimer Holdings Inc. lifted their price target on Mirna Therapeutics from $7.00 to $13.00 and gave the company an “outperform” rating in a research report on Tuesday, August 16th. Finally, Leerink Swann lowered Mirna Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $10.00 to $4.00 in a research report on Monday, August 15th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $7.38.

Mirna Therapeutics (NASDAQ:MIRN) opened at 2.46 on Wednesday. The company’s market cap is $51.25 million. Mirna Therapeutics has a 52 week low of $2.21 and a 52 week high of $11.01. The firm has a 50-day moving average price of $3.17 and a 200-day moving average price of $4.12.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/cantor-fitzgerald-downgrades-mirna-therapeutics-inc-mirn-to-hold.html

Mirna Therapeutics Company Profile

Mirna Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of microRNA (ribonucleic acid)-based oncology therapeutics. It is developing a cancer therapy, microRNA Replacement Therapy, focused on replacing naturally occurring microRNAs that are under expressed in cancer cells with microRNA mimics.

5 Day Chart for NASDAQ:MIRN

The Fly

Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.